0 products, total $0.+86-400-890-9989      Login |  Register 中文한국어

Browse By Molecule:

Your Position: Home > Recombinant Protein > Human Cell Expressed > CD55 / DAF Protein

CD55 / DAF Protein PDF Download

Catalog Size (Price) Quantity In Stock Operation Other Information
10101-H02H
  YES          

Complement Decay-accelerating Factor Protein ( CD55 / DAF ) Datasheet

 

CD55 / DAF Protein Price Information

CD55 / DAF Protein Product Information

Synonym: RP11-357P18.1, CR, CROM, DAF, TC
Protein Construction: A DNA sequence encoding the human CD55 precursor (NP_000565.1 ) ( Met 1- Ser 353 ) was expressed with the C-terminal fused Fc region of human IgG1
Source: Human
Expression Host: Human Cell

CD55 / DAF Protein QC Testing

Purity: > 90 % as determined by SDS-PAGE SDS-PAGE:
SDS-PAGE
Bio-activity :

Measured by its binding ability in a functional ELISA
Immobilized recombinant human CD97 at 10μg/ml ( 100μl/well ) can bind recombinant human CD55 at a linear range of  0.46 - 30 μg/ml

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
Stability: Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal: Asp 35
Molecular Mass: The recombinant human CD55/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 557 amino acids and has a predicted molecular mass of 61.7 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rhCD55/Fc monomer is approximately 95-105 kDa due to glycosylation.
Formulation:

Lyophilized from sterile PBS , pH 7.4

  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.

 

CD55 / DAF Protein Usage Guide

Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage and usage. Avoid repeated freeze-thaw cycles.

CD55 / DAF Protein Related Products & Topics

Related Areas:

Immunology>>Innate Immunity>>Complement System>>CD55/DAF

Immunology>>Cluster of Differentiation>>Other>>CD55/DAF

Proteins:

CD55/DAF Human CD55/DAF Protein, Recombinant 10101-H08H
CD55/DAF Mouse CD55 / DAF Protein, Recombinant 50468-M08H

Antibodies:

Human
CD55/DAF
WB, ELISA Mouse Monoclonal Antibody 10101-MM03
Human
CD55/DAF
WB, ELISA CD55/DAF Antibody, Rabbit MAb 10101-R028
Human
CD55/DAF
WB, ELISA Rabbit Polyclonal Antibody 10101-RP01

CD55 / DAF Protein Description

CD55, also well known as decay-accelerating factor (DAF), is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. This 70-75 kDa glycoprotein CD55 containing four SCR modules is involved in the regulation of the complement cascade. It interferes with the functions of C3 and C5 convertases in both the classical and alternative pathways by preventing the assembly of the C3bBb complex or accelerating the disassembly of preformed convertase, and thus disrupts the cascade and protects the host cells from damage. Antigens present on the CD55/DAF constitute determinant for the Cromer blood group system. CD55/DAF has been identified as a ligand for an activation-associated, seven-transmembrane lymphocyte receptor, CD97, which is a receptor mediating attachment and infection of several viruses and bacteria. In addition, it has been shown that CD55/DAF regulates the interplay between complement and T cell immunity in vivo, and thus may be implicated in immune and tumor biology. There are two variants of CD55 encoded by alternatively spliced transcripts, the predominant variant is a GPI-anchored membrane form ubiquitously expressed on cells exposed to plasma complement proteins, whereas a soluble form present at much lower level.

References

  1. Bergelson, J.M. et al., 1994, Proc. Natl. Acad. Sci. USA. 91: 6245-6248.
  2. Terstappen, L.W. et al., 1992, J. Leuro. Biol. 52: 652-660.
  3. Liu, J. et al., 2005, J. Exp. Med. 201: 567-577.
  4. Madjd, Z. et al., 2004, Clin. Cancer. Res. 10: 2797-2803.
  5. Mikesch, J.H. et al., 2007, Cell. Oncol. 28: 223-232.

 

CD55 / DAF related areas, pathways, and other information